The healthcare & pharma category is going through a time of transformation, due to continued economic uncertainty, evolving consumer dynamics, and a heightened focus on health and wellness. Consumers and brands alike are increasingly focused on healthcare accessibility, from expansion of services to treatment affordability, especially when it comes to mental health.
Facing increased competition and volatile consumer perception, the Healthcare & Pharma category will continue to be more innovative and nimble to creative consumer connections and keep pace with evolving consumer behaviors.
For more information, please contact Megan Ryan.
By 2029, the market is expected to grow to $791B (4.7% CAGR), driven largely by anticipated oncology drugs
+6% increase in expected drug approvals in ’25 (69 expected approvals) vs. ’24 (65 expected approvals)
By 2028, U.S. national healthcare expenditure is estimated to reach $6.2T
